BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
Avenzo Therapeutics, Inc.
Avenzo Therapeutics, Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Ascendis Pharma A/S
Hoffmann-La Roche
Icahn School of Medicine at Mount Sinai
National Cancer Institute (NCI)
7 Hills Pharma, LLC
Merck Sharp & Dohme LLC
Crescent Biopharma, Inc.
Beijing Biotech
Parabilis Medicines, Inc.
Memorial Sloan Kettering Cancer Center
Eikon Therapeutics
Pfizer
Beijing Biotech
Lumos Pharma
ModernaTX, Inc.
Verastem, Inc.
M.D. Anderson Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Incyclix Bio
Ipsen
Aulos Bioscience, Inc.
Ipsen
Arsenal Biosciences, Inc.
iOnctura
Hoffmann-La Roche
AstraZeneca
Beijing Biotech
Regeneron Pharmaceuticals
Artios Pharma Ltd
Novartis
M.D. Anderson Cancer Center
Frontier Medicines Corporation
Beijing Biotech
GI Innovation, Inc.
PMV Pharmaceuticals, Inc
Mayo Clinic
University of Southern California
Crinetics Pharmaceuticals Inc.
Memorial Sloan Kettering Cancer Center
Baptist Health South Florida
M.D. Anderson Cancer Center
Engeneic Pty Limited
Ascendis Pharma A/S
Avenzo Therapeutics, Inc.
Tasca Therapeutics
Essen Biotech
Essen Biotech